SRPT Sarepta Therapeutics Inc.

88.05
+2.35  (+3%)
Previous Close 85.7
Open 85.67
Price To Book 5.95
Market Cap 6,545,673,717
Shares 74,340,417
Volume 924,598
Short Ratio
Av. Daily Volume 1,958,520
Stock charts supplied by TradingView

NewsSee all news

  1. Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

    -- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression and biomarker data

  2. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were

  3. Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

    CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Friday, Oct. 4, 2019 at 8:00 a.m.

  4. CLASS ACTION UPDATE for CTST, JE, VAL and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  5. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 8, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) ("Sarepta" or the "Company") of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing due 2H 2019.
Casimersen (SRP-4045) - ESSENCE
Duchenne muscular dystrophy
Phase 1/2 dosing to be completed 2Q 2019.
Microdystrophin gene therapy
Duchenne muscular dystrophy
Aims to have dosing and safety insight by 1H 2020.
SRP-5051 - PPMO
Duchenne muscular dystrophy
CRL issued August 19, 2019.
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 complete. Protocol update enabling IV delivery Phase 1/2a trial planned 2018
MYO-102
Duchenne muscular dystrophy - LGMD2D
Phase 1/2 9-month data presented October 4, 2019 improvements in functional outcomes in all three participants.
MYO-101 (SRP-9003)
Duchenne muscular dystrophy - LGMD2E
Phase 2/3 initiation of dosing announced February 14, 2019.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)
Phase 2 Study 2 readout due by end of 2020.
SRP-9001
Duchenne muscular dystrophy

Latest News

  1. Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

    -- Improvements on functional measures seen in all three participants -- -- Significant reduction in creatine kinase maintained over nine months -- -- Results follow positive and robust expression and biomarker data

  2. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were

  3. Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy

    CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Friday, Oct. 4, 2019 at 8:00 a.m.

  4. CLASS ACTION UPDATE for CTST, JE, VAL and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  5. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 8, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) ("Sarepta" or the "Company") of

  6. FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MMM, GTT, PS and SRPT

    CEDARHURST, N.Y., Sept. 06, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies.

  7. IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  8. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    New York, New York--(Newsfile Corp. - September 5, 2019) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)("Sarepta" or the "Company")

  9. IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati

  10. Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79, The Duchenne

  11. Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT)

    NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) in the

  12. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    NEW YORK, Sept. 5, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) of the

  13. CLASS ACTION UPDATE for JE, TWOU, EVH and SRPT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

  14. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Sarepta Therapeutics, Inc. To Contact The Firm

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT) of the October

  15. SHAREHOLDER ALERT - Sarepta Therapeutics, Inc. (SRPT) - Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action and Lead Deadline: October 29, 2019

    NEW YORK, Sept. 4, 2019 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta"

  16. Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the

  17. INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Sarepta Therapeutics, Inc.

    --(BUSINESS WIRE)--The law firm of

  18. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2019, that were previously

  19. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

    NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT).   Such investors are advised to

  20. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sarepta Therapeutics, Inc.

    NEW YORK, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an investigation of Sarepta Therapeutics, Inc. ("Sarepta or "the Company") (NASDAQ:SRPT) concerning possible